Abcam, ab140415, Recombinant Human beta Synuclein protein

Size: 20µg / 50µg
Recombinant Human beta Synuclein protein is a Human Full Length protein, in the 1 to 134 aa range, expressed in Escherichia coli, with >95%, suitable for SDS-PAGE, WB.
Key facts
Purity:>95% Densitometry,
Expression system:Escherichia coli,
Tags:His tag N-Terminus,
Applications:WB, SDS-PAGESee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:No,
Accession:Q16143,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 7Preservative: 1.02% ImidazoleConstituents: 25% Glycerol (glycerin, glycerine), 1.75% Sodium chloride, 0.82% Sodium phosphate, 0.004% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.002% PMSF

Properties and Storage Information:
Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--80°C, Appropriate long-term storage conditions--80°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Beta-synuclein also known as β-synuclein or SNCB is a protein that plays a role in the nervous system. It is a small protein with a molecular weight around 14 kDa. Predominantly beta-synuclein is found in presynaptic terminals of neurons in the central nervous system including the brain and spinal cord. This protein shares significant amino acid sequence identity with alpha-synuclein and gamma-synuclein comprising the synuclein family. It acts as a modulator of neuronal and synaptic function influencing the dynamics of neurotransmitter release.
Biological function summary
Beta-synuclein contributes to cellular homeostasis and synaptic integrity. It is not typically found as part of a larger protein complex like its relative alpha-synuclein which forms toxic aggregates. Instead beta-synuclein exhibits neuroprotective properties helping maintain neuronal health. It possibly regulates synaptic vesicle cycling and mitigates levels of alpha-synuclein aggregation. Research suggests that loss of beta-synuclein function might disrupt synaptic stability leading to neurological issues.
Pathways
Beta-synuclein engages in synaptic function and plasticity. It participates in pathways related to neurotransmitter release and synaptic vesicle trafficking. Beta-synuclein is connected to calcium/calmodulin-dependent protein kinase II (CaMKII) pathways. This interaction supports beta-synuclein's regulatory impact on synaptic vesicle dynamics negatively modulating the aggregation-prone behaviors seen in alpha-synuclein during synucleinopathies.
Beta-synuclein plays a role in neurodegenerative diseases like Parkinson’s disease and dementia with Lewy bodies. Research highlights its relationship with these conditions due to its interaction with alpha-synuclein known to form pathological aggregates and contribute to disease progression. Beta-synuclein's modulation of alpha-synuclein activity can impact the development and progression of these disorders. There is ongoing interest in its potential protective role suggesting it might be leveraged in therapeutic strategies against synucleinopathy-related diseases.